The objective of this study is to explore and validate a novel prognostic index for patients with locally advanced or metastatic biliary tract cancer (BTC) treated with first‐line therapy with cisplatin, gemcitabine, and durvalumab.
M. Persano, A. Casadei-Gardini, L. Fornaro et al.· Cancer· 0 citations
BACKGROUND
The impact of circulating tumour DNA (ctDNA) detection, which informs minimal residual disease (MRD) after curative treatment, remains debated especially for stage IV patients.
OBJECTIVE
The study objectives were to evaluate the prognostic role of MRD and to estimate lead time (LT) at different timepoints...
G. Maddalena, K. Aziz, Ryan Sun et al.· Gut· 0 citations
ABSTRACT Background & Aims The management of comorbidities has become increasingly relevant in unresectable hepatocellular carcinoma (uHCC) as immunotherapy prolongs survival. Atezolizumab plus bevacizumab (AB) is a standard first‐line option, but bevacizumab carries a risk of cardiovascular toxicities. Data on cardiov...
B. Stefanini, L. Rimassa, M. Iavarone et al.· Liver international (Print)· 0 citations
PURPOSE Comprehensive genomic profiling (CGP) is increasingly adopted in the management of patients affected by GI cancers. However, the applicability, performance, and clinical utility of CGP in the real-world setting are still undefined. METHODS We retrospectively evaluated CGP performance and clinical benefit in con...
G. Maddalena, Valentina Angerilli, F. Nichetti et al.· JCO Precision Oncology· 0 citations
Simple Summary Squamous cell carcinoma of the anal canal (SCAC) is a rare malignancy whose incidence has been increasing worldwide. The main etiological factor is HPV infection, particularly in association with HIV infection and other immunosuppressive conditions. The majority of patients present with localized disease...
Matilde Callegarin, Valentina Angerilli, J. Gasparello et al.· Cancers· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
